Structurally Defined Tandem-responsive Nanoassemblies Composed of Dipeptide-based Photosensitive Derivatives and Hypoxia-activated Camptothecin Prodrugs Against Primary and Metastatic Breast Tumors
Overview
Authors
Affiliations
Substantial progress in the use of chemo-photodynamic nano-drug delivery systems (nano-DDS) for the treatment of the malignant breast cancer has been achieved. The inability to customize precise nanostructures, however, has limited the therapeutic efficacy of the prepared nano-DDS to date. Here, we report a structurally defined tandem-responsive chemo-photosensitive co-nanoassembly to eliminate primary breast tumor and prevent lung metastasis. This both-in-one co-nanoassembly is prepared by assembling a biocompatible photosensitive derivative (pheophorbide-diphenylalanine peptide, PPA-DA) with a hypoxia-activated camptothecin (CPT) prodrug [(4-nitrophenyl) formate camptothecin, N-CPT]. According to computational simulations, the co-assembly nanostructure is not the classical core-shell type, but consists of many small microphase regions. Upon exposure to a 660 nm laser, PPA-DA induce high levels of ROS production to effectively achieve the apoptosis of normoxic cancer cells. Subsequently, the hypoxia-activated N-CPT and CPT spatially penetrate deep into the hypoxic region of the tumor and suppress hypoxia-induced tumor metastasis. Benefiting from the rational design of the chemo-photodynamic both-in-one nano-DDS, these nanomedicines exhibit a promising potential in the inhibition of difficult-to-treat breast tumor metastasis in patients with breast cancer.
Potential of epithelial membrane protein 3 as a novel therapeutic target for human breast cancer.
Wang Y, Tuan Y, Wang J, Chang H, Chu C, Chen Y Oncol Rep. 2024; 53(1).
PMID: 39611484 PMC: 11632653. DOI: 10.3892/or.2024.8849.
Stimuli-activatable nanomedicine meets cancer theranostics.
Li H, Feng Y, Luo Q, Li Z, Li X, Gan H Theranostics. 2023; 13(15):5386-5417.
PMID: 37908735 PMC: 10614691. DOI: 10.7150/thno.87854.
Zhu Y, Ouyang Z, Du H, Wang M, Wang J, Sun H Acta Pharm Sin B. 2022; 12(11):4011-4039.
PMID: 36386472 PMC: 9643300. DOI: 10.1016/j.apsb.2022.08.022.
Carrier-free supramolecular nanoassemblies of pure LSD1 inhibitor for effective anti-tumor therapy.
Li B, Zhang X, Li J Front Chem. 2022; 10:1012882.
PMID: 36247676 PMC: 9561089. DOI: 10.3389/fchem.2022.1012882.